Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014869
Filing Date
2024-11-07
Accepted
2024-11-07 16:15:57
Documents
57
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nxtc-20240930x10q.htm   iXBRL 10-Q 1203866
2 EX-31.1 nxtc-20240930xex31d1.htm EX-31.1 12905
3 EX-31.2 nxtc-20240930xex31d2.htm EX-31.2 12686
4 EX-32.1 nxtc-20240930xex32d1.htm EX-32.1 12252
  Complete submission text file 0001558370-24-014869.txt   5201383

Data Files

Seq Description Document Type Size
5 EX-101.SCH nxtc-20240930.xsd EX-101.SCH 29754
6 EX-101.CAL nxtc-20240930_cal.xml EX-101.CAL 41324
7 EX-101.DEF nxtc-20240930_def.xml EX-101.DEF 109678
8 EX-101.LAB nxtc-20240930_lab.xml EX-101.LAB 325694
9 EX-101.PRE nxtc-20240930_pre.xml EX-101.PRE 216330
60 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20240930x10q_htm.xml XML 900992
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38905 | Film No.: 241435987
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)